Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment

International Journal of Psychiatry in Clinical Practice

Volumn 16, Issue 2, 2012, Pages 148-152

  Mahmoud, Ahmed ^a   Hayhurst, Karen P ^a   Drake, Richard J ^a   Lewis, Shôn W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antipsychotic drugs; Antipsychotic treatment; Atypical drugs; Schizophrenia; Sexual dysfunction

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ARTICLE; CONTROLLED STUDY; DEROGATIS INTERVIEW FOR SEXUAL FUNCTIONING; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; SEXUAL FUNCTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF REPORT; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 84860848828     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.625122     Document Type: Article

References (26)

1. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23:201-9
2. Goff DC, Shader RI. Non-neurological side-effects of antipsychotic drugs. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. 2nd ed. Massachusetts, US: Blackwell; 2003
3. Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66:331-8
4. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170: 463-7
5. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49-55
6. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28
7. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003;9:344-53
8. Bobes J, García-Portilla MP, Rejas J, Hernández G, Garcia- Garcia M, Rico-Villademoros F, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-47
9. Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-43
10. Mahmoud A, Hayhurst KP, Drake RJ, Lewis SW. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial. Schizophr Res Treat 2011:Article ID 596898, 6 p, doi:10.1155/2011/ 596898
11. Derogatis LR. The Derogatis Interview for Sexual Function (DISF/DISF-SR): an introductory report. J Sex Marital Ther 1997;23:291-304
12. BNF. British National Formulary. London: BMJ Publishing Group; 2007
13. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust NZ J Psychiatry 2004;38:240-5
14. M üller MJ, Wetzal H, Eich F-X, Rein W, Puech A, Benkert O. Dose-related effects of amisulpride on fi ve dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2002;22:554-60
15. W ilkie A, Preston N, Wesby R. High dose neuroleptics - who gives them and why? Psychiatr Bull 2001;25:179-83
16. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7
17. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-8
18. Hanssens L, L' I talien G, Loze J-Y, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in communitytreated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95
19. Harrington M, Lelliott P, Paton C, Okocha C, Duffett R, Sensky T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psych Bull 2002;26:414-8
20. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. Br Med J 1999;319:312-5
21. Hegeler S, Mortensen M. Sexuality and ageing. Br J Sex Med 1978;5:16-19
22. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085-97
23. Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW and the EUFEST Study Group. Sexual dysfunction in fi rst-episode schizophrenia patients. Results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011;31:274-80
24. Mackin P, Waton A, Nulkar A, Watkinson HM. Prolactin and smoking status in antipsychotic-treated patients. J Psychopharmacol 2010;25:698-703
25. Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007;20:138-42
26. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2003;182:199-204